Levi Garraway, Roche CMO
At two-year follow-up, Evrysdi continues to show numerical improvements in data, Roche says
A little less than two months after receiving an FDA approval in spinal muscular atrophy, Roche’s Genentech continues to roll out data for risdiplam …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
